【摘 要】
:
Objective: The triple negative breast cancer patients has higher rates of local reccurence and distant metastasis and poorer survival.How to improve the treatment benefits for this group is becoming t
【机 构】
:
Department of Radiation Oncology, Kunming Medical University Yunnan Provincial Cancer Hospital, Yunn
【出 处】
:
第五届全国肿瘤诊疗新进展及新技术学术会议暨第八届中国西部肿瘤学术大会
论文部分内容阅读
Objective: The triple negative breast cancer patients has higher rates of local reccurence and distant metastasis and poorer survival.How to improve the treatment benefits for this group is becoming the focus for oncologists.Our aim is to detect whether surgical bed boost for triple negative breast cancer patients is associated with a difference in local failure rates and overall survival.Methods: We retrospectively reviewed the medical records of 40 cases of triple negative patients out of 399 consecutive breast cancer patients who were treated with adjuvant radiotherapy between 2004 and 2008 at our institution.Twenty cases receive a boost and twenty cases did not.No boost patients receive total dose of EBRT of 42.4-50Gy/16-25 fractions.Patients in the boost group received an additional 10-15 Gy/4-6 fractions to the tumor bed.There is no difference with T stage, surgery type and margin states (P > 0.001).The T stage:T0 7(17.5%) ;T1 7(17.5%) ;T2 20(50%) ;T3 3(7.5%) ;T4 3(7.5%).The lumpectomy in different stage is 85.7%, 85.7% ,90.0% ,66.7% ,66.7% retrospectively.The clear margin in each group is 85.7% ,85.7% ,85.7% ,90%, 100% ,66.7% retrospectively.Our observed outcomes were overall survival(OS), disease-free survival(DFS), local(LFR) and distant failure rates (DFR) using the statastatsitical software.Results:The median follow-up from date of diagnosis was 53.5 months (44.0-63.0 months).The OS for boost and no boost was 90% vs.85% and the DFS was 70% vs.70% for triple-negative subtypes.There was no difference between the two groups (P > 0.01).There was also no difference in local and distant failure rates respectively 85% vs.70% and 85 % vs.75% (P > 0.01).Conclusions:In our series, radiotherapy boost does not appear to improve local control and overall survivalin triple negative breast cancer.This warrants further nestigations.
其他文献
目的:探讨黄芩素对肝癌MHCC97H细胞侵袭转移的抑制作用及其分子机制.方法:采用肿瘤细胞迁移划痕实验和Transwell侵袭小室的方法检测黄芩素对体外肝癌细胞迁徙和侵袭的抑制作用.RT-PCR方法检测黄芩素对肝癌MH-CC97H细胞MMP-2、-9和u-PA转录的抑制作用.明胶酶谱法检测黄芩素对MHCC97H细胞MMP-2、-9和u-PA酶活性的影响.Western blot法检测黄芩素对MHC
目的:建立小鼠原位移植性肝癌模型,观察脾脏在肿瘤进展过程中的变化,探讨脾脏在肿瘤免疫中的作用.方法:BALB/c小鼠33只,其中将24只小鼠分为正常组、荷瘤1周、2周、3周组,每组6只,其余9只荷瘤小鼠用于观察生存期.模型组于肝脏原位注射2×105个H22肝癌细胞,分别在荷瘤1周、2周和3周称量脾脏重量、计算脾指数,光镜下用HE染色观察脾脏的形态学变化,并用流式细胞术的方法观察荷瘤不同时期脾脏中髓
目的:观察肝硬化门脉高压症脾亢脾对人肝癌细胞生长增殖的影响及相关机制,探索一条从脾脏入手防治肝癌的新途径.方法:选取肝硬化门脉高压症脾功能亢进行脾切除的患者作为实验组,健康成年人、乙肝患者、乙肝肝硬化不伴脾亢患者为对照组.收集以上各组的外周血清、脾亢患者脾切除术中脾血清.培养不同转移潜能的人肝癌细胞株(HepG2、SMMC-7721、MHCC97-H),上述各组血清作用于不同时间点(24、48、7
目的:从人结肠癌细胞株中分离、鉴定结肠癌侧群细胞(side population,SP)的存在,并初步观察其生物学特性.方法:利用流式细胞仪(flow cytometry analysis,FCM)检测SP细胞,无血清悬浮成球培养,然后检测自我更新、分化能力、克隆形成能力,增殖和浸润能力,细胞周期、化疗耐药和肿瘤成瘤情况.利用RT-PCR和Western blot检测干细胞相关基因的表达水平.结果
目的:观察不同浓度菝葜皂苷元对体外培养的胃癌BGC-823细胞凋亡相关蛋白Bax和Bcl-2表达的影响.方法:BGC-823细胞经不同浓度(12.5、25、50μg/ml)菝葜皂苷元处理后,采用流式细胞仪检测细胞凋亡,免疫细胞化学方法检测Bcl-2、Bax的表达.结果:随着菝葜皂苷元浓度的增加,BGC-823细胞凋亡率、Bax表达增加,而Bcl-2表达减少.结论:菝葜皂苷元可诱导BGC-823细胞
目的:探讨去细胞处理对肿瘤细胞外基质骨架成分、结构及组织稳定性的影响,为确立构建体外三维肿瘤提供依据.方法:我们以人肺癌A549肿瘤细胞种植免疫缺陷鼠所得肿瘤组织块为材料,切成薄片后接受不同方法的去细胞处理,组织化学染色了解细胞去除程度.新鲜和去细胞处理的肿瘤组织片(n=10)分别进行DNA、胶原和氨基聚糖含量检测;对细胞去除彻底的Tris-Trypsin-Triton和SDS组孔隙率和机械性能进
目的:观察siRNA对人肝癌细胞PLC/PRF/5和肝癌细胞HUH-7增殖活性的影响并初步探讨其可能的机制。方法:在培养液中加入不同浓度的siRNA后,细胞计数并绘制生长曲线,MTT法检测细胞增殖,流式细胞仪检测细胞周期及凋亡情况。结果:细胞计数发现处理组的细胞数明显低于对照组;MTT法检测细胞增殖显示siRNA可以抑制人肝癌细胞PLC/PRF/5和肝癌细胞HUH-7的增殖,有一定的时间和剂量依赖
目的:探讨组蛋白去乙酰化转移酶抑制剂MS-275对不同胃癌细胞株(MNK45和SGC7901)生长及凋亡的影响,并初步探讨其机制。方法:用不同浓度MS-275分别处理体外培养的MNK45和SGC7901细胞株,用WST-1法检测对细胞的增殖抑制作用;流式细胞仪和TUNEIL法检测细胞凋亡情况;Western blot检测p53含量变化。结果:MS-275可以抑制胃癌细胞株的生长且呈时间和浓度依赖性
目的:探讨诱导细胞死亡的DFF45样效应因子-3(cell death-inducing DFF45-like effector-3,CIDE-3)对肝癌细胞凋亡功能的影响,为完善HCC病因学及筛选出HCC治疗新靶点提供依据.方法:构建CIDE-3的真核表达载体,通过脂质体转染方法获得CIDE-3高表达的稳定转染以及瞬转HCC细胞株,从而来观察CIDE-3对肝癌细胞增殖和凋亡的影响.结果:成功构建
目的:探讨抑制microRNA-21(miR-21)的表达对大肠癌细胞生物学行为及PTEN表达的影响,并分析miR-21参与肿瘤发生、发展的可能机制.方法:应用细胞瞬转的方法将miR-21 inhibitor转染大肠癌细胞HCT116,应用细胞增殖试验(CCK8方法)、流式细胞技术(FCM)、Transwell侵袭和迁移试验、荧光素酶试验检测抑制大肠癌细胞HCT116细胞株中miR-21表达后,对